Paying users zone. Data is covered by hidden.

  • Get to Abbott Laboratories for $17.99, or

  • get to whole website for at least 3 months from $49.99.


Statement of Cash Flows
Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company's cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company's statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, Consolidated Statement of Cash Flows (quarterly data)

USD $ in millions

Microsoft Excel LibreOffice Calc
3 months ended Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013
Net earnings (loss) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Depreciation hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Amortization of intangible assets hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Share-based compensation hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Impact of currency devaluation hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Amortization of inventory step-up hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Gain on sale of businesses hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Mylan N.V. equity investment adjustment hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Gain on sale of Mylan N.V. shares hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net loss on extinguishment of debt hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Trade receivables hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Inventories hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Other, net hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Adjustments to reconcile net earnings (loss) to net cash from (used in) operating activities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net cash from (used in) operating activities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Acquisitions of property and equipment hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Acquisitions of businesses and technologies, net of cash acquired hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Proceeds from business dispositions hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Proceeds from the sale of Mylan N.V. shares hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
(Purchases) sales of other investment securities, net hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net cash (used in) from investing activities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net borrowings (repayments) of short-term debt and other hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Proceeds from the issuance of long-term debt hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Repayments of long-term debt hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Payment of bridge financing fees hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Purchase of Alere preferred stock hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Payment of contingent consideration hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Transfer of cash and cash equivalents to AbbVie Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Purchases of common shares hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Proceeds from stock options exercised hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Dividends paid hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net cash from (used in) financing activities hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Effect of exchange rate changes on cash and cash equivalents hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net increase (decrease) in cash and cash equivalents hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-06), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-07), 10-K (filing date: 2014-02-21), 10-Q (filing date: 2013-11-07), 10-Q (filing date: 2013-08-06), 10-Q (filing date: 2013-05-08).

Item Description The company
Net cash from (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories's net cash from (used in) operating activities increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018.
Net cash (used in) from investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories's net cash (used in) from investing activities declined from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018.
Net cash from (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories's net cash from (used in) financing activities increased from Q1 2018 to Q2 2018 and from Q2 2018 to Q3 2018.